Healthcare
Vycor Medical, Inc.(VYCO)
Live Price
Offline$0.066
+0.00% today
1Y Change
-42.61%
Window
Jun 23, 2025 โ Jun 18, 2026
- Market Cap
- โ
- Revenue Growth
- +17.2%
- EPS Growth
- -260.6%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 23, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Vycor Medical, Inc. (VYCO) is a Healthcare stock with listed on OTC. The stock last traded around $0.07 and down 42.6% across the available one-year price window (Jun 23, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +17.2%, EPS growth of -260.6%, a dividend yield of 0.0%. What stands out right now is revenue +17.2%, EPS -260.6%, free cash flow -133.4% with operating margin 1.8% and ROIC -1.1%. Valuation is more restrained than many high-expectation growth names at price/sales 1.2. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines VYCO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+17.2% vs +7.6% peer median
Operating Margin
Below sector median
+1.8% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 13, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +17.2% and EPS is at -260.6%, with operating margin around 1.8%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +2.6% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 13, 2026 | โ | +0.0% | +0.0% | +0.0% |
2026 Apr 13, 2026 | โ | +7.7% | +7.7% | +7.7% |
2025 Nov 14, 2025 | โ | +0.0% | +0.0% | -8.6% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VYCO
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
VYCO Max Drawdown
-71.50%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for VYCO and SPY.
Company Overview
Vycor Medical, Inc.
Other OTC
Vycor Medical, Inc. designs, develops, and markets neurological medical devices and therapies in the United States and Europe. It operates in two segments, Vycor Medical and NovaVision. The Vycor Medical segment provides devices for neurosurgery comprising ViewSite Brain Access System, a retraction and access system for brain and spine surgeries. The NovaVision segment offers non-invasive computer-based rehabilitation targeted at people who have impaired vision as a result of stroke or other brain injury. Vycor Medical, Inc. has a license and transition agreement with HelferApp GmbH, which grants HelferApp the license to provide NovaVision's products and therapies to patients and professionals in Austria and Switzerland. The company primarily serves hospitals and medical professionals. Vycor Medical, Inc. was incorporated in 2005 and is headquartered in Boca Raton, Florida. Vycor Medical, Inc. is a subsidiary of Fountainhead Capital Management Limited.
- Leadership
- Peter C. Zachariou
- IPO Date
- Jan 16, 2013
- Employees
- 7
- Street Address
- 951 Broken Sound Boulevard
- Mailing
- Boca Raton, FL, 33487
- Region
- Boca Raton, FL, US
- Reporting Currency
- USD
- Investor Line
- 561 558 2000
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 39.5
- Price/Sales
- 1.2
- Price/Book
- โ
Growth
- Revenue
- +17.2%
- EPS
- -260.6%
- Free Cash Flow
- -133.4%
Profitability
- Gross Margin
- 83.8%
- Operating Margin
- 1.8%
- Net Margin
- -3.9%
- ROE
- 1.8%
- ROIC
- -1.1%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.12
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.